# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 31-40 of 568 results.
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Mar 13, 2019
First Received: Apr 07, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Biological samples collection
Locations: CHU Caen, Caen, France
Hopital Henri Mondor, Creteil, France
CHU Le Bocage, Dijon, France
CH Départemental, La Roche sur Yon, France
CHU Claude Hurriez, Lille, France
... and 11 other locations.
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: Mar 13, 2019
First Received: Mar 13, 2019
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Pembrolizumab and CXD101
A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Jun 05, 2019
First Received: May 05, 2016
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Rituximab (RTX), MOR208, Bendamustine (BEN)
Locations: MorphoSys Research Site, Anaheim, California, United States
MorphoSys Research Site, Bakersfield, California, United States
Morphosys Research Site, Burbank, California, United States
Morphosys Research Site, Fresno, California, United States
MorphoSys Research Site, Los Angeles, California, United States
... and 162 other locations.
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jun 28, 2019
First Received: Sep 28, 2018
Disease(s): Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Intervention(s): INCB053914, INCB050465
Locations: University of Arizona Cancer Center, Tucson, Arizona, United States
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
Clinical Research Alliance, Lake Success, New York, United States
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: May 30, 2019
First Received: Dec 17, 2018
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): TQB2303, Rituximab
Locations: No.150 Haping Road, Nangang District, Haerbin, Heilongjiang, China
No. 42 Baiziting Road, Xuanwu District, Nanjing, Jiangsu, China
No.8 Jiangtan Road,Weibin District, Baoji, China
No. 87 Xiangya Road Furong District, Changsha, China
No.138 Tongzipo Road Yuelu District, Changsha, China
... and 27 other locations.
18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Oct 08, 2019
First Received: Apr 20, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): 18F-FDG PET SCAN, MRI DIFFUSION
Locations: Centre antoine-LACASSAGNE, Nice, France
CART-19 Cells for R/R B-cell Lymphoma
Status: Recruiting
Last Changed: Jan 05, 2018
First Received: Jan 05, 2018
Disease(s): Relapsed or Refractory B-cell Lymphoma
Intervention(s): CART-19 cells
Locations: Fujian Medical University Union Hospital, Fuzhou, Fujian, China
A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Not yet recruiting
Last Changed: Sep 14, 2018
First Received: Sep 14, 2018
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): JHL1101, MabThera
Locations: Beijing Cancer Hospital, Beijing, Beijing, China
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Apr 27, 2016
First Received: Apr 27, 2016
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): bendamustine, rituximab
Locations: Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy
Status: Recruiting
Last Changed: Oct 03, 2019
First Received: Sep 19, 2018
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Mosunetuzumab, Tocilizumab
Locations: University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica, Santa Monica, California, United States
University of Miami Sylvester Comprehensive Center, Miami, Florida, United States
Fort Wayne Medical Institute, Fort Wayne, Indiana, United States
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
... and 16 other locations.